NASDAQ:RDHL - RedHill Biopharma Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $19.80
  • Forecasted Upside: 185.71 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.18 (-2.53%)

This chart shows the closing price for RDHL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New RedHill Biopharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RDHL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RDHL

Analyst Price Target is $19.80
▲ +185.71% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for RedHill Biopharma in the last 3 months. The average price target is $19.80, with a high forecast of $26.00 and a low forecast of $12.00. The average price target represents a 185.71% upside from the last price of $6.93.

This chart shows the closing price for RDHL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 investment analysts is to buy stock in RedHill Biopharma. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/21/2021HC WainwrightReiterated RatingBuy$23.00Low
7/14/2021HC WainwrightReiterated RatingBuy$23.00Medium
6/29/2021HC WainwrightReiterated RatingBuy$23.00Medium
6/1/2021Roth CapitalReiterated RatingBuyHigh
6/1/2021HC WainwrightReiterated RatingBuyHigh
5/31/2021BTIG ResearchReiterated RatingBuy$26.00Low
5/28/2021WBB SecuritiesDowngradeStrong-Buy ➝ Buy$17.00 ➝ $16.00High
5/18/2021HC WainwrightInitiated CoverageBuy$23.00High
11/12/2020Roth CapitalLower Price TargetBuy$16.00 ➝ $12.00High
10/13/2020Ascendiant Capital MarketsReiterated RatingBuy$22.00High
9/11/2020BTIG ResearchInitiated CoverageBuy$26.00High
3/5/2020HC WainwrightReiterated RatingBuy$18.00 ➝ $14.00Medium
2/27/2020Roth CapitalLower Price Target$20.25 ➝ $15.00Medium
11/20/2019HC WainwrightReiterated RatingBuy$18.00Medium
11/4/2019HC WainwrightReiterated RatingBuy$18.00Medium
10/21/2019HC WainwrightSet Price TargetBuy$16.00Low
7/12/2019WBB SecuritiesUpgradeBuy ➝ Strong-Buy$17.00High
7/8/2019Ascendiant Capital MarketsSet Price TargetBuy$23.00Medium
3/12/2019WBB SecuritiesUpgradeSpeculative Buy ➝ Buy$17.00High
2/27/2019HC WainwrightReiterated RatingReduce ➝ Buy$16.00Medium
1/14/2019HC WainwrightSet Price TargetBuy$36.00High
12/31/2018WBB SecuritiesInitiated CoverageBuy$5.36Medium
12/12/2018LADENBURG THALM/SH SHSet Price TargetBuy$24.00Medium
11/14/2018HC WainwrightSet Price TargetBuy$36.00High
10/23/2018HC WainwrightSet Price TargetBuy$36.00Low
7/31/2018HC WainwrightReiterated RatingBuyHigh
7/2/2018HC WainwrightReiterated RatingBuy$36.00High
6/25/2018LADENBURG THALM/SH SHInitiated CoverageBuy$20.00Low
5/9/2018HC WainwrightSet Price TargetBuy$36.00High
1/26/2018Nomura SecuritiesInitiated CoverageBuy$18.00High
11/21/2017HC WainwrightReiterated RatingBuy$36.00N/A
11/14/2017Roth CapitalLower Price TargetBuy$27.00 ➝ $20.00N/A
10/6/2017Seaport Global SecuritiesInitiated CoverageBuy ➝ Buy$19.00N/A
10/4/2017Roth CapitalReiterated RatingBuy$27.00Medium
10/4/2017HC WainwrightReiterated RatingBuy ➝ Buy$33.00 ➝ $36.00Low
9/13/2017UBS GroupInitiated CoverageReduceMedium
7/31/2017Roth CapitalSet Price TargetBuy$27.00High
7/26/2017HC WainwrightSet Price TargetBuy$33.00High
6/16/2017(FBRC)Reiterated RatingBuyLow
6/15/2017HC WainwrightSet Price TargetBuy$33.00Low
5/4/2017Roth CapitalSet Price TargetBuy$26.00Low
5/4/2017HC WainwrightSet Price TargetBuy$33.00Low
4/5/2017(FBRC)Reiterated RatingBuyLow
2/25/2017HC WainwrightSet Price TargetBuy$33.00N/A
2/24/2017(FBRC)Reiterated RatingOutperform ➝ Outperform$36.00 ➝ $25.00N/A
12/14/2016(FBRC)Reiterated RatingBuyN/A
11/16/2016(FBRC)Reiterated RatingBuyN/A
10/12/2016(FBRC)Reiterated RatingOutperform$36.00N/A
10/7/2016HC WainwrightSet Price TargetBuy$33.00N/A
10/6/2016(FBRC)Reiterated RatingBuyN/A
9/9/2016(FBRC)Reiterated RatingBuyN/A
8/25/2016(FBRC)Reiterated RatingOutperform$36.00N/A
7/27/2016(FBRC)Boost Price TargetOutperform$33.00 ➝ $36.00N/A
(Data available from 7/25/2016 forward)
RedHill Biopharma logo
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focused on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 1/2a study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and Phase 2a study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; and RHB-106, an encapsulated formulation for bowel preparation, which has completed Phase 2a study. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
Read More

Today's Range

Now: $6.93
Low: $6.81
High: $7.12

50 Day Range

MA: $6.90
Low: $5.97
High: $7.43

52 Week Range

Now: $6.93
Low: $5.90
High: $11.52


221,143 shs

Average Volume

311,243 shs

Market Capitalization

$321.55 million

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of RedHill Biopharma?

The following Wall Street analysts have issued stock ratings on RedHill Biopharma in the last year: Ascendiant Capital Markets, BTIG Research, HC Wainwright, Roth Capital, WBB Securities, and Zacks Investment Research.
View the latest analyst ratings for RDHL.

What is the current price target for RedHill Biopharma?

5 Wall Street analysts have set twelve-month price targets for RedHill Biopharma in the last year. Their average twelve-month price target is $19.80, suggesting a possible upside of 185.7%. BTIG Research has the highest price target set, predicting RDHL will reach $26.00 in the next twelve months. Roth Capital has the lowest price target set, forecasting a price of $12.00 for RedHill Biopharma in the next year.
View the latest price targets for RDHL.

What is the current consensus analyst rating for RedHill Biopharma?

RedHill Biopharma currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RDHL will outperform the market and that investors should add to their positions of RedHill Biopharma.
View the latest ratings for RDHL.

What other companies compete with RedHill Biopharma?

How do I contact RedHill Biopharma's investor relations team?

RedHill Biopharma's physical mailing address is 21 Ha'arba'a Street, Tel Aviv L3, 64739. The biotechnology company's listed phone number is 972-3541-3131 and its investor relations email address is [email protected] The official website for RedHill Biopharma is